VRTX Stock Risk & Deep Value Analysis
Vertex Pharmaceuticals Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About VRTX Stock
We analyzed Vertex Pharmaceuticals Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran VRTX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
How Risky Is VRTX Stock?
Overall Risk
Moderate
Financial Risk
Low
Market Risk
Low
Competitive Risk
Medium
Execution Risk
Low
Regulatory Risk
Medium
What Are the Red Flags for VRTX?
- ⚠
Unexpected clinical trial failures or delays for key pipeline assets
- ⚠
Regulatory setbacks or unfavorable reimbursement decisions for Casgevy or VX-548
- ⚠
Emergence of a highly competitive or superior therapy in new markets
- ⚠
Post-marketing safety concerns for recently approved therapies
Unlock VRTX Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Vertex Pharmaceuticals Inc (VRTX) Do?
Market Cap
$116.24B
Sector
Healthcare
Industry
Biotechnology
Employees
6,100
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; and Entrada Therapeutics, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Visit Vertex Pharmaceuticals Inc WebsiteIs VRTX Stock Undervalued?
Unlock the full AI analysis for VRTX
Get the complete DVR score, risk analysis, and more
Is VRTX Financially Healthy?
P/E Ratio
31.95
Does VRTX Have a Competitive Moat?
Sign in to unlockMoat Rating
🏰 Wide
Moat Trend
Expanding
Moat Sources
3 Identified
Vertex's moat is durable, primarily driven by its extensive patent portfolio and regulatory exclusivities for its highly effective Cystic Fibrosis drugs. Its expansion into gene editing and T1D also creates new, defensible IP assets and first-mover advantages that will be difficult for competitors to replicate.
Moat Erosion Risks
- •Long-term patent expirations of older CF drugs without sufficient pipeline replacement
- •New disruptive technologies from competitors in emerging markets
- •Government price controls or unfavorable reimbursement policy changes
VRTX Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive VRTX Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (estimated late April 2026)
- •Additional global regulatory approvals and reimbursement agreements for Casgevy (0-6 months)
- •Updated clinical data or regulatory progress for VX-548 in ex-US markets (if US approval in 2025)
Medium-Term (6-18 months)
- •Further pipeline readouts and advancements in Type 1 Diabetes (VX-880/VX-264) (6-18 months)
- •Expanded commercial launch and sales ramp-up for VX-548 globally (6-18 months)
- •Strategic partnerships or acquisitions to bolster pipeline in new therapeutic areas
Long-Term (18+ months)
- •Establishment of multi-billion dollar franchises beyond CF, particularly in gene editing and T1D (18+ months)
- •Advancement of next-generation CF therapies through pipeline
- •Significant market penetration in non-opioid pain market with VX-548
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for VRTX?
- ✓
Acceleration in Casgevy global uptake and sales figures
- ✓
Positive Phase 3 data and successful commercial launch of VX-548
- ✓
Significant positive clinical data readouts for Type 1 Diabetes programs (VX-880/VX-264)
Bull Case Analysis
See what could go right with Premium
Compare VRTX to Similar Stocks
See how Vertex Pharmaceuticals Inc stacks up against related companies in our head-to-head analysis.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for VRTX (Vertex Pharmaceuticals Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
